Spyre Me Up: Selling the $85 Put on SYRE's IBD Breakthrough
Spyre Therapeutics just posted proof-of-concept data across all three components of its IBD combination pipeline — and the market has spent the last few weeks deciding how much it cares. With SYRE sit
Atlas Portfolio results referenced in this post are produced in a simulation environment using EOD market data and contract pricing. They are not records of trades placed in a brokerage account or executed with real capital, and individual results would vary based on fills, commissions, slippage, and account size. Tiblio is a software platform for finding and executing options trade ideas. We are not a registered investment advisor or broker-dealer. Nothing in this post is financial advice. Options trading involves substantial risk of loss. Past or simulated performance does not guarantee future results.